# Maharashtra FDA cancels Cipla Pune warehouse licences 2026-10-02T17:10:47+00:00 | Governance | Indian Opinion Desk Corroboration: 4 independent outlets The Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's warehouse at Vadki, Pune, after fresh proceedings over the misbranding of Reactin Plus Tablets and storage deficiencies. The action followed a revised show-cause notice on 4 September, a written reply from Cipla on 11 September, and a personal hearing on 21 September. The licensing authority issued the cancellation order on 1 October. The FDA said the packaging of Reactin Plus, a Schedule H prescription drug, carried unauthorised claims describing it as an analgesic and depicting relief from muscular pain, constituting misbranding under the Drugs and Cosmetics Act, 1940. Inspections also found medicines stored on the floor, dust accumulation, expired stock not segregated, and discrepancies between computer records and physical inventory. The earlier proceedings of 27 August were withdrawn following Bombay High Court directions, and the fresh order was described as an independent regulatory decision. ## Indian Opinion Analysis The coverage is uniform across all four outlets: straight agency-style reporting of the FDA statement, with no outlet foregrounding the company's defence or criticising the regulator. The Economic Times, Indian Express, Rediff, and The Federal all lead with the cancellation, detail the misbranding and storage lapses, and quote FDA Commissioner Tukaram Mundhe on the department's aim to ensure medicine safety and compliance. No outlet omits the fact that the proceedings followed Bombay High Court directions. The consensus indicates a clear regulatory narrative with no significant editorial divergence. ## Coverage Coverage: 4 sources, 4 neutral - economictimes.indiatimes.com (neutral report) Leads with FDA statement, no editorialising - indianexpress.com (neutral report) Straight news report, quotes commissioner - rediff.com (neutral report) Key points summary, wire-like structure - thefederal.com (neutral report) PTI wire copy, no added commentary This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Tags: Bombay High Court, Cipla, Maharashtra FDA, Pune, Reactin Plus Canonical: https://indianopinion.org/maharashtra-fda-cancels-cipla-pune-warehouse-licences/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/maharashtra-fda-cancels-cipla-pune-warehouse-licences/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/